Results for this period
Interim period (second quarter)1 March 2026 to 31 August 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Expansion of the scale of operations, improvement of operating efficiency and strengthening of the earnings base; acquisition of a pharmaceutical wholesaling business in Saga Prefecture; higher utilization rates at new facilities in the healthcare business and the effects of newly consolidated subsidiaries; steady sales at the 3 newly added pharmaceutical wholesalers and existing branches and sales offices; and higher prescription drug prices in the dispensing pharmacy business.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 March 2026 to 31 August 2026 |
| Net Sales | ¥28,255 million (YoY +4.9%) |
| Operating profit | ¥821 million (YoY +10.4%) |
| Ordinary income | ¥1,135 million (YoY +29.0%) |
| Profit attributable to owners of the parent | ¥850 million (YoY +27.5%) |
| Net income per share | ¥225.77 |
| Equity ratio | End of the current fiscal period 42.7 / End of previous period 41.7 |
| Total assets | ¥37,521 million |
| Net assets | ¥16,692 million |
| Cash flows from operating activities | ¥2,440,981 thousand |
| Cash flows from investing activities | ¥67,432 thousand |
| Cash flows from financing activities | ¥-1,136,845 thousand |
| Cash and cash equivalents at end of period | ¥7,121,358 thousand |
| Full-year earnings forecast | Net Sales ¥56,500 million (YoY +2.8%) / Operating profit ¥1,800 million (YoY +0.7%) / Ordinary income ¥1,850 million (YoY -0.5%) / Net income ¥1,300 million (YoY +2.0%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥120 → ¥120（0.0%） |
| Segment revenue | Dispensing Pharmacy Business ¥13,215 million (YoY +1.2%), Healthcare Business ¥4,685 million (YoY +6.9%), Pharmaceutical Wholesale Business ¥10,219 million (YoY +9.0%), Real Estate Business ¥135 million (YoY +12.2%) |
| Segment profit | Dispensing Pharmacy Business ¥610 million (YoY -7.2%), Healthcare Business ¥44 million (YoY +212.6%), Pharmaceutical Wholesale Business ¥148 million (YoY +66.3%), Real Estate Business ¥81 million (YoY +7.7%) |
| Depreciation and amortization | ¥363,339 thousand |
| Impairment loss | ¥10,947 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥129,531 thousand, Gain on sale of investment securities ¥371,010 thousand / Extraordinary loss Loss on sale of fixed assets ¥994 thousand, Loss on Disposal of Fixed Assets ¥2,133 thousand, Impairment Losses ¥10,947 thousand, Loss on sale of investment securities ¥5 thousand, Loss on rights fees ¥265,000 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name None |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 3,770,000 |
| Treasury Shares at Period-End | 4,365 |
| Factors Behind Changes in Business Performance | Expansion of the scale of operations, improvement of operating efficiency and strengthening of the earnings base; acquisition of a pharmaceutical wholesaling business in Saga Prefecture; higher utilization rates at new facilities in the healthcare business and the effects of newly consolidated subsidiaries; steady sales at the 3 newly added pharmaceutical wholesalers and existing branches and sales offices; and higher prescription drug prices in the dispensing pharmacy business. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company said that contributions came from expanding the scale of its operations, improving operating efficiency and strengthening its earnings base, as well as the acquisition of a pharmaceutical wholesaling business in Saga Prefecture, higher utilization rates at new facilities, contributions from newly consolidated subsidiaries, and steady sales at the 3 newly added pharmaceutical wholesalers and existing branches and sales offices.